Changes of Feno and Nasal NO Levels after Treatment in Pediatric Allergic Rhinitis
Monday, March 7, 2016
South Exhibit Hall H (Convention Center)
Jin-A Jung, MD, Woo Yong Bae, MD, Ja Hyeong Kim, MD
Rationale: The fractional concentration of exhaled NO (FeNO) has been shown to be increased in inflammatory airway diseases, including bronchial asthma (BA), allergic rhinitis(AR), and chronic rhinosinusitis. In the present study, we examined the differences of oral FeNO and nasal FeNO levels in AR patients with or without BA.

Methods: In the cross-sectional study, 31 patients with mild-persistent or severe-intermittent AR patients, 23 AR patients with BA, and 19 normal subjects were enrolled. The FeNO levels were measured by using a handheld electrochemical analyzer (NObreathⓇ; Bedfont Scientific LTd., Rochester, Kent, UK) before treatment and at one month after treatment. The nasal FeNO levels were measured by using a nose adaptor. All patients were measured serum total eosinophil count, total IgE, allergen-specific IgE against six common aeroallergens by the ImmunoCAP or skin prick test.

Results: The oral FeNO levels before and after treatment showed no significant differences between AR and AR with BA. The nasal FeNO levels before treatment were significantly higher in the AR with BA than the AR(P=0.005). After treatment, the nasal FeNO levels were no significant differences between diseases groups. The nasal FeNO levels after treatment were significantly lower compared to the nasal FeNO levels before treatment in both AR and AR with BA(AR; P=0.044, AR with BA; P=0.004).

Conclusions: The nasal FeNO measurement in AR patients is suitable method for monitoring the effect of treatment.